Orexigen shares hit by FDA delay in obesity drug

Orexigen Therapeutics shares fell 15 percent after the FDA delayed its decision on the drug pending post-marketing safety monitoring requirements.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.